NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022

Phase 2a trial meets enrollment target for interim analysis and is now more than 50% enrolled 21 clinical sites in the United States actively enrolling patients Nearly 90% of patients completing the trial have opted into the Open Label Extension study